Evommune (EVMN) Net Margin (2025)
Evommune (EVMN) posted quarterly Net Margin of 124.75% for Q3 2025, up 74.4% quarter-over-quarter from 487.3% in Q1 2025.
Evommune (EVMN) Net Margin (2025) Analysis & Trends
Evommune (EVMN) has reported Net Margin for 1 consecutive years, with 124.75% the latest figure, recorded in Q3 2025.
- In Q3 2025, Net Margin changed N/A year-over-year to 124.75%; the TTM figure through Mar 2026 stood at 1299.76% (changed N/A YoY), while the FY2025 annual figure was 1017.32%, down 5202.0% from the prior year.
- Net Margin grew to 124.75% in Q3 2025 per EVMN's latest filing, from 487.3% in the prior quarter.
- Across five years, Net Margin topped out at 124.75% in Q3 2025 and bottomed at 487.3% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Evommune | 531.53 Mn | 330.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -124.75% |
| Mar 31, 2025 | -487.30% |